Press Releases Keyword Search Year None20262025202420232022202120202019201820172016201520142013 August 5, 2026 Editas Medicine Announces Second Quarter 2026 Results and Business Updates August 4, 2026 Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D. May 28, 2026 Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference May 26, 2026 Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering May 26, 2026 Editas Medicine Announces Proposed Public Offering May 26, 2026 Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress May 14, 2026 Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting May 5, 2026 Editas Medicine Announces First Quarter 2026 Results and Business Updates April 27, 2026 Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences March 27, 2026 Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference Pagination Current page 1 Page 2 Next page next › Last page last »
August 4, 2026 Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.
May 26, 2026 Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
May 14, 2026 Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
April 27, 2026 Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences
March 27, 2026 Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
